The DOI matches its Crossref record; 263 of the 263 references it cites were found in a registry or an index.
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Open accessAbstract
Alzheimer's disease (AD) is the most common cause of dementia and accounts for 60-70 % of all cases. It affects millions of people worldwide. AD poses a substantial economic burden on societies and healthcare systems. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. As the prevalence of AD continues to increase, understanding its pathogenesis, improving diagnostic methods, and developing effective therapeutics have become paramount. This comprehensive review delves into the intricate mechanisms underlying AD, explores the current state of diagnostic techniques, and examines emerging therapeutic strategies. By revealing the complexities of AD, this review aims to contribute to the growing body of knowledge surrounding this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Oxidative Stress: Harms and Benefits for Human Health
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8416763 · Cited by 4,837
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 2×
“Improving early and accurate diagnostic methods is crucial for identifying individuals at the earliest stages of AD, facilitating early interventions and clinical trials (Deture and Dickson, 2019).”
BackgroundA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019) · Molecules · doi:10.3390/molecules24081583 · Cited by 2,254
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“Chronic inflammation within the brain, often referred to as neuro-inflammation, is a prominent feature observed in AD patients and has been implicated in disease progression (Kinney et al., 2018).”
BackgroundKurutas, E. B. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0186-5 · Cited by 2,152
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Bhatti, J. S., Bhatti, G. K., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.010 · Cited by 1,655
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513 · cited 1×
“In AD, microglia are activated by A β plaques via various cell surface receptors like CD14, TLR4-TLR6 heterodimer, CD36-CD47-α 6 β 1-integrin complex, and scavenger receptors (Stewart et al., 2009; Bamberger et al., 2024; Liu et al., 2005; Paresce et al., 1996).”
BackgroundOxidative stress, mitochondrial damage and neurodegenerative diseases.
Guo, C., Sun, L., Chen, X., & Zhang, D. (2013) · PubMed · doi:10.3969/j.issn.1673-5374.2013.21.009 · Cited by 1,298
Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Targeting abnormal tau aggregation and its associated downstream consequences is a promising avenue for potential disease-modifying treatments (Congdon and Sigurdsson, 2018).”
BackgroundArtificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,061
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
Adult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Spector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterworth, M., & Orrell, M. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.3.248 · Cited by 876
Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., et al. (2019) · Science · doi:10.1126/science.aav2546 · Cited by 813
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744 · cited 1×
“The development of disease-modifying treatments that can slow or halt disease progression is a major research goal (van der Flier et al., 2023; Porsteinsson et al., 2021).”
BackgroundThe blood–brain barrier in systemic infection and inflammation
Galea, I. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00757-x · Cited by 738
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Domains of cognition and their assessment
Harvey, P. D. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.3/pharvey · Cited by 695 · cited 1×
“(Harvey, 2019).”
Ruegsegger, G. N., & Booth, F. W. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029694 · Cited by 690
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Paresce, D. M., Ghosh, R. N., & Maxfield, F. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80187-7 · Cited by 663
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654 · cited 1×
“Mitochondria, the cellular power-houses responsible for energy production, are particularly susceptible to oxidative damage due to their high metabolic activity and generation of ROS as natural byproducts of oxidative phosphorylation (Misrani et al., 2021; Guo et al., 2013).”
BackgroundAssociation of sleep duration in middle and old age with incidence of dementia
Sabia, S., Fayosse, A., Dumurgier, J., van Hees, V. T., Paquet, C., Sommerlad, A., Kivimäki, M., Dugravot, A., & Singh-Manoux, A. (2021) · Nature Communications · doi:10.1038/s41467-021-22354-2 · Cited by 628
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight
Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Sochocka, M., Donskow-Łysoniewska, K., Diniz, B. S., Kurpas, D., Brzozowska, E., & Leszek, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1188-4 · Cited by 584 · cited 1×
“Permeability to the blood brain barrier is increased due to the overproduction of LPS in the gut, which is a consequence of gut microbiota dysbiosis (Sochocka et al., 2019).”
BackgroundArvanitakis, Z., Capuano, A. W., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30029-1 · Cited by 581
Anandatheerthavarada, H. K., Biswas, G., Robin, M.-A., & Avadhani, N. G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207030 · Cited by 571 · cited 1×
“Moreover, A β -induced mitochondrial damage can trigger a vicious cycle, as impaired mitochondrial function further promotes A β production and aggregation (Anandatheerthavarada et al., 2003).”
BackgroundAlzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Litvinchuk, A., Wan, Y.-W., Swartzlander, D. B., Chen, F., Cole, A., Propson, N. E., Wang, Q., Zhang, B., Liu, Z., & Zheng, H. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.031 · Cited by 523
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Bahar-Fuchs, A., Clare, L., & Woods, B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003260.pub2 · Cited by 507
Brain plasticity and functional losses in the aged: scientific bases for a novel intervention
Mahncke, H. W., Bronstone, A., & Merzenich, M. M. (2006) · Progress in Brain Research · doi:10.1016/s0079-6123(06)57006-2 · Cited by 504
A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
Ewers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M., Petersen, R. C., Jack, C. R., Feldman, H. H., Bokde, A. L. W., Alexander, G. E., Scheltens, P., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.019 · Cited by 394
Impact of dementia: Health disparities, population trends, care interventions, and economic costs
Aranda, M. P., Kremer, I. N., Hinton, L., Zissimopoulos, J., Whitmer, R. A., Hummel, C. H., Trejo, L., & Fabius, C. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17345 · Cited by 390
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365
Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics
Lucey, B. P., Hicks, T. J., McLeland, J. S., Toedebusch, C. D., Boyd, J., Elbert, D. L., Patterson, B. W., Baty, J., Morris, J. C., Ovod, V., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25117 · Cited by 362
Blood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide
Liu, Y., Walter, S., Stagi, M., Cherny, D., Letiembre, M., Schulz-Schaeffer, W., Heine, H., Penke, B., Neumann, H., & Fassbender, K. (2005) · Brain · doi:10.1093/brain/awh531 · Cited by 349
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 337
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335
Ben Haim, L., Ceyzériat, K., Carrillo-de Sauvage, M. A., Aubry, F., Auregan, G., Guillermier, M., Ruiz, M., Petit, F., Houitte, D., Faivre, E., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3516-14.2015 · Cited by 335
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12321 · Cited by 330
Le Douce, J., Maugard, M., Veran, J., Matos, M., Jégo, P., Vigneron, P.-A., Faivre, E., Toussay, X., Vandenberghe, M., Balbastre, Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.004 · Cited by 328
Fox, N. C., & Freeborough, P. A. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070620 · Cited by 325
The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?
Megur, A., Baltriukienė, D., Bukelskienė, V., & Burokas, A. (2020) · Nutrients · doi:10.3390/nu13010037 · Cited by 323
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.753 · Cited by 319
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · cited 1×
“McDade et al. reported changes in A β and p-tau levels in the CSF 25 and 10 years before disease onset in patients with dominantly inherited AD (McDade et al., 2018; Lle ´ o et al., 2019).”
BackgroundMicrobiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease
Bairamian, D., Sha, S., Rolhion, N., Sokol, H., Dorothée, G., Lemere, C. A., & Krantic, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00522-2 · Cited by 314
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
Jack, C. R., Slomkowski, M., Gracon, S., Hoover, T. M., Felmlee, J. P., Stewart, K., Xu, Y., Shiung, M., O’Brien, P. C., Cha, R., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000042480.86872.03 · Cited by 297
Rajeev, V., Fann, D. Y., Dinh, Q. N., Kim, H. A., De Silva, T. M., Lai, M. K. P., Chen, C. L.-H., Drummond, G. R., Sobey, C. G., & Arumugam, T. V. (2022) · Theranostics · doi:10.7150/thno.68304 · Cited by 296
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“Lecanemab acts similarly to Aducanumab and has a higher binding affinity to large soluble A β aggregates (Tucker et al., 2015).”
BackgroundNeuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis
Bradburn, S., Murgatroyd, C., & Ray, N. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.002 · Cited by 268
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Genetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Reza-Zaldivar, E. E., Hernández-Sapiéns, M. A., Gutiérrez-Mercado, Y. K., Sandoval-Ávila, S., Gomez-Pinedo, U., Márquez-Aguirre, A. L., Vázquez-Méndez, E., Padilla-Camberos, E., & Canales-Aguirre, A. A. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.255978 · Cited by 256
Ismail, R., Parbo, P., Madsen, L. S., Hansen, A. K., Hansen, K. V., Schaldemose, J. L., Kjeldsen, P. L., Stokholm, M. G., Gottrup, H., Eskildsen, S. F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01820-6 · Cited by 255
Role of structural MRI in Alzheimer's disease
Vemuri, P., & Jack, C. R. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt47 · Cited by 244
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242 · cited 1×
“Mutations in the PSEN1 gene on chromosome 14 and in the PSEN2 gene on chromosome 1 result in abnormal processing of the APP protein and subsequent increased A β production (Tcw and Goate, 2017; Petit et al., 2022).”
BackgroundHashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.676 · Cited by 242
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Cummings, J. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 241
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Merrill, C. A., Jonsson, M. A. G., Minthon, L., Ejnell, H., Silander, H. C.-S., Blennow, K., Karlsson, M., Nordlund, A., Rolstad, S., Warkentin, S., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0801 · Cited by 236
Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview
Sivandzade, F., & Cucullo, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042153 · Cited by 224
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220
SHENG, J. G., MRAK, R. E., & T. GRIFFIN, W. S. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199703000-00007 · Cited by 215
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Role of p38/MAPKs in Alzheimer's Disease: Implications for Amyloid Beta Toxicity Targeted Therapy
Kheiri, G., Dolatshahi, M., Rahmani, F., & Rezaei, N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0008 · Cited by 211 · cited 1×
“Several p38 MAPK inhibitors, such as MW181 and NJK14047, were studied in vivo (Kheiri et al., 2018).”
BackgroundShahpasand, K., Uemura, I., Saito, T., Asano, T., Hata, K., Shibata, K., Toyoshima, Y., Hasegawa, M., & Hisanaga, S.-I. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5927-11.2012 · Cited by 206 · cited 1×
“Abnormal phosphorylation and aggregation of tau can impair mitochondrial transport along neuronal axons, leading to local energy deficits and oxidative stress (Shahpasand et al., 2012).”
Inflammation context in Alzheimer’s disease, a relationship intricate to define
Novoa, C., Salazar, P., Cisternas, P., Gherardelli, C., Vera-Salazar, R., Zolezzi, J. M., & Inestrosa, N. C. (2022) · Biological Research · doi:10.1186/s40659-022-00404-3 · Cited by 206
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease
Guo, M., Yin, Z., Chen, F., & Lei, P. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00670-x · Cited by 200
Hudry, E., Van Dam, D., Kulik, W., De Deyn, P. P., Stet, F. S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougnères, P., Aubourg, P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.175 · Cited by 198
Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., Reback, E., Porter, V., Swerdloff, R., & Cummings, J. L. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.nct50002 · Cited by 197
Spector, A., Orrell, M., & Woods, B. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2464 · Cited by 196
Is Mild Cognitive Impairment Prodromal for Vascular Dementia Like Alzheimer’s Disease?
Meyer, J. S., Xu, G., Thornby, J., Chowdhury, M. H., & Quach, M. (2002) · Stroke · doi:10.1161/01.str.0000024432.34557.10 · Cited by 195
Roy, R. G., Mandal, P. K., & Maroon, J. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00486 · Cited by 194
Carpenter, C. R., Bassett, E. R., Fischer, G. M., Shirshekan, J., Galvin, J. E., & Morris, J. C. (2011) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2011.01040.x · Cited by 193
CSF Biomarkers for Alzheimer's Disease Diagnosis
Anoop, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/606802 · Cited by 193
Vasconcelos, B., Stancu, I.-C., Buist, A., Bird, M., Wang, P., Vanoosthuyse, A., Van Kolen, K., Verheyen, A., Kienlen-Campard, P., Octave, J.-N., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1525-x · Cited by 192
Sodium Oligomannate: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177
Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge?
Fabrizio, C., Termine, A., Caltagirone, C., & Sancesario, G. M. (2021) · Diagnostics · doi:10.3390/diagnostics11081473 · Cited by 177
The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes
Ross, R. E., VanDerwerker, C. J., Saladin, M. E., & Gregory, C. M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01819-w · Cited by 176
Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial
Amieva, H., Robert, P. H., Grandoulier, A. A., Meillon, C., de Rotrou, J., Andrieu, S., Berr, C., Desgranges, B., Dubois, B., Girtanner, C., et al. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215001830 · Cited by 176
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H.-Y., & Lin, C.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 176
Hempen, B., & Brion, J.-P. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199609000-00003 · Cited by 175
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
Liu, Y., Tan, Y., Zhang, Z., Yi, M., Zhu, L., & Peng, W. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00397-x · Cited by 173
Vemuri, P., Whitwell, J. L., Kantarci, K., Josephs, K. A., Parisi, J. E., Shiung, M. S., Knopman, D. S., Boeve, B. F., Petersen, R. C., Dickson, D. W., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.05.012 · Cited by 172
Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G., Gupta, S. K., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 166
Li, X.-C., Hu, Y., Wang, Z.-H., Luo, Y., Zhang, Y., Liu, X.-P., Feng, Q., Wang, Q., Ye, K., Liu, G.-P., et al. (2016) · Scientific Reports · doi:10.1038/srep24756 · Cited by 164
Liu, Y., Chu, J. M. T., Yan, T., Zhang, Y., Chen, Y., Chang, R. C., & Wong, G. T. C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1653-7 · Cited by 163
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., et al. (2022) · Cells · doi:10.3390/cells11081367 · Cited by 163
Fortea, J., Vilaplana, E., Alcolea, D. A., Carmona‐Iragui, M., Sánchez‐Saudinós, M., Sala, I., Antón‐Aguirre, S., González‐Ortiz, S., Medrano, S., Pegueroles, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24186 · Cited by 160
Kim, H. J., Cho, K. R., Jang, H., Lee, N. K., Jung, Y. H., Kim, J. P., Lee, J. I., Chang, J. W., Park, S., Kim, S. T., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00897-2 · Cited by 159
Invited review: Prion‐like transmission and spreading of tau pathology
Clavaguera, F., Hench, J., Goedert, M., & Tolnay, M. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12197 · Cited by 156
Hatami, A., Monjazeb, S., Milton, S. C. F., & Glabe, C. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755264 · Cited by 151
Rojo, L. E., Alzate‐Morales, J. H., Saavedra, I. N., Davies, P., & Maccioni, R. B. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1262 · Cited by 150
Vascular risk factors and Alzheimer’s disease
Cechetto, D. F., Hachinski, V., & Whitehead, S. N. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.743 · Cited by 149
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Maphis, N., Jiang, S., Xu, G., Kokiko-Cochran, O. N., Roy, S. M., Van Eldik, L. J., Watterson, D. M., Lamb, B. T., & Bhaskar, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0221-y · Cited by 147 · cited 1×
“In aged hTau mice, MW181 reversed tau phosphorylation and prevented cognitive deterioration (Maphis et al., 2016).”
BackgroundTau as a Biomarker of Neurodegenerative Diseases
Schraen‐Maschke, S., Sergeant, N., Dhaenens, C., Bombois, S., Deramecourt, V., Caillet‐Boudin, M., Pasquier, F., Maurage, C., Sablonnière, B., Vanmechelen, E., et al. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.363 · Cited by 143
Hey, J. A., Yu, Y., Versavel, M., Abushakra, S. R., Kočiš, P., Power, A., Kaplan, P. L., Amedio, J. C., & Tolar, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 141
Wang, H., Yang, F., Zhang, S., Xin, R., & Sun, Y. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00213-7 · Cited by 141
Zhang, S., Han, D., Tan, X., Feng, J., Guo, Y., & Ding, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02845.x · Cited by 140
Lleó, A., Alcolea, D. A., Martínez‐Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa‐Neto, P., Slot, R. E. R., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.01.015 · Cited by 139
Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk
Passaro, A. P., Lebos, A. L., Yao, Y., & Stice, S. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676621 · Cited by 138
Choi, S., Aïd, S., Caracciolo, L., Minami, S., Niikura, T., Matsuoka, Y., Turner, R. S., Mattson, M. P., & Bosetti, F. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12059 · Cited by 137
The Clock Drawing Test A review of its accuracy in screening for dementia
Aprahamian, I., Martinelli, J. E., Neri, A. L., & Yassuda, M. S. (2009) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642009dn30200002 · Cited by 137
Metabolic and inflammatory adaptation of reactive astrocytes: role of PPARs
Iglesias, J., Morales, L., & Barreto, G. E. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9833-2 · Cited by 137
Human neural stem cell transplantation improves cognition in a murine model of Alzheimer’s disease
McGinley, L. M., Kashlan, O. N., Bruno, E. S., Chen, K. S., Hayes, J. M., Kashlan, S. R., Raykin, J., Johe, K. K., Murphy, G. G., & Feldman, E. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-33017-6 · Cited by 137
Pharmacological advances in mitochondrial therapy
Singh, A., Faccenda, D., & Campanella, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103244 · Cited by 137
Biomarkers for Alzheimer’s Disease in the Current State: A Narrative Review
Gunes, S., Aizawa, Y., Sugashi, T., Sugimoto, M., & Rodrigues, P. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094962 · Cited by 135
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
Lowe, S. L., Willis, B. A., Hawdon, A., Natanegara, F., Chua, L., Foster, J., Shcherbinin, S., Ardayfio, P. A., & Sims, J. R. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12112 · Cited by 128
Ríos, A. S., Oxenford, S., Neudorfer, C., Butenko, K., Li, N., Rajamani, N., Boutet, A., Elias, G. J. B., Germann, J., Loh, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34510-3 · Cited by 126
TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment
Zhou, Y., Chen, Y., Xu, C., Zhang, H., & Lin, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602508 · Cited by 125
Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
Petit, D., Fernández, S. G., Zoltowska, K. M., Enzlein, T., Ryan, N. S., O’Connor, A., Szaruga, M., Hill, E., Vandenberghe, R. R., Fox, N. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01518-6 · Cited by 124
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease
Apodaca, L. A., Baddour, A. A. D., Garcia, C., Alikhani, L., Giedzinski, E., Ru, N., Agrawal, A., Acharya, M. M., & Baulch, J. E. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00791-x · Cited by 122
Chen, W.-T., Hong, C., Lin, Y.-T., Chang, W.-H., Huang, H.-T., Liao, J., Chang, Y.-J., Hsieh, Y.-F., Cheng, C.-Y., Liu, H.-C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035807 · Cited by 120
Kuller, L. H., López, O. L., Mackey, R. H., Rosano, C., Edmundowicz, D., Becker, J. T., & Newman, A. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.034 · Cited by 117
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Aisen, P. S. S. (2005) · CNS Drugs · doi:10.2165/00023210-200519120-00002 · Cited by 113
Gee, M. S., Son, S. H., Jeon, S. H., Do, J., Kim, N., Ju, Y., Lee, S. J., Chung, E. K., Inn, K., Kim, N., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00617-2 · Cited by 112
Quintana-Hernández, D. J., Miró-Barrachina, M. T., Ibáñez-Fernández, I. J., Pino, A. S.-D., Quintana-Montesdeoca, M. P., Rodríguez-de Vera, B., Morales-Casanova, D., Pérez-Vieitez, M. D. C., Rodríguez-García, J., & Bravo-Caraduje, N. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-143009 · Cited by 107
Hernandez, P., Lee, G., Sjoberg, M., & Maccioni, R. B. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0933 · Cited by 107 · cited 1×
“A β aggregation promotes tau phosphorylation by activating kinases like GSK β , CDK-5 (Hernandez et al., 2009; Terwel et al., 2008).”
BackgroundBelaya, I., Ivanova, M., Sorvari, A., Ilicic, M., Loppi, S. H., Koivisto, H., Varricchio, A., Tikkanen, H. O., Walker, F. R., Atalay, M., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01935-w · Cited by 107
Gene therapy in Alzheimer’s disease – potential for disease modification
Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B. G., & Saido, T. C. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01038.x · Cited by 104
Grothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 104
Du, F., Yu, Q., Kanaan, N. M., & Yan, S. S. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddab363 · Cited by 104
Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Medina, M., & Ávila, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793176581 · Cited by 103
Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death
Liu, M., Sui, D., Dexheimer, T. S., Hovde, S., Deng, X., Wang, K., Lin, H. L., Hagar, H. C., Kweon, H. K., Kuo, N. S., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02034-w · Cited by 103
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer’s Disease: A Review
Vargas‐Caballero, M., Warming, H., Walker, R., Holmes, C., Cruickshank, G. S., & Patel, B. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.866434 · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
The Role of Diet and Gut Microbiota in Alzheimer’s Disease
Dissanayaka, D. M. S., Jayasena, V., Rainey‐Smith, S. R., Martins, R. N., & Fernando, W. M. A. D. B. (2024) · Nutrients · doi:10.3390/nu16030412 · Cited by 99
Informal Caregiving and Alzheimer’s Disease: The Psychological Effect
Hellis, E., & Mukaetova-Ladinska, E. B. (2022) · Medicina · doi:10.3390/medicina59010048 · Cited by 98
Acat1 Knockdown Gene Therapy Decreases Amyloid-β in a Mouse Model of Alzheimer's Disease
Murphy, S. R., Chang, C. C., Dogbevia, G., Bryleva, E. Y., Bowen, Z., Hasan, M. T., & Chang, T.-Y. (2013) · Molecular Therapy · doi:10.1038/mt.2013.118 · Cited by 96
Sheffield, L. G., Marquis, J. G., & Berman, N. E. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01037-5 · Cited by 96
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 96
Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 92
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z. K., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 90
Kim, D., Cho, J., & Kang, H. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112105 · Cited by 87
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
Ramanan, V. K., & Day, G. S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00637-0 · Cited by 85
Karisetty, B. C., Bhatnagar, A., Armour, E. M., Beaver, M., Zhang, H., & Elefant, F. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.577622 · Cited by 83
A review of neuroimaging biomarkers of Alzheimer's disease.
Varghese, T., Sheelakumari, R., James, J. S., & Mathuranath, P. S. (2013) · PubMed · Cited by 82
Structured Group Reminiscence: An Intervention for Older Adults
Stinson, C. K. (2009) · The Journal of Continuing Education in Nursing · doi:10.3928/00220124-20091023-10 · Cited by 82
Li, N.-M., Li, N., Liu, K., Zhang, H.-H., Nakanishi, H., & Qing, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.247469 · Cited by 76
Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation
Saroja, S. R., Gorbachev, K., Julia, T., Goate, A. M., & Pereira, A. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108870119 · Cited by 75
Arora, S., Kanekiyo, T., & Singh, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.203 · Cited by 75
Mesenchymal Stem Cell Therapy and Alzheimer’s Disease: Current Status and Future Perspectives
Kim, J., Lee, Y., Lee, S., Kim, K., Song, M., & Lee, J. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200219 · Cited by 73
Attenuation of microglial activation in a mouse model of Alzheimer’s disease via NFAT inhibition
Rojanathammanee, L., Floden, A. M., Manocha, G. D., & Combs, C. K. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0255-2 · Cited by 73
Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 71
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction
Gireud, M., Mack, A. F., McCullough, L. D., & Urayama, A. (2020) · The Neuroscientist · doi:10.1177/1073858420954811 · Cited by 70
Choi, M., Kim, H.-J., Yang, E.-J., & Kim, H.-S. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.05.009 · Cited by 69
Research works printed but not linked: 21
- Suzuki, 2023, Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase γ-Secretase Sensitivity and Modulate Amyloid-β Production, Int J. Mol. Sci. [Internet], 24, 24
- Fu, 2017, Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation, J. Neuroinflamm. [Internet], 14, 1
- Cha, 2012, Mitochondria-Specific Accumulation of Amyloid β Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death, PLoS One [Internet], 7
- Li, 2015, Different mechanisms of apolipoprotein E isoform–dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia, FASEB J. [Internet]
- Mecca, 2022, Synaptic density and cognitive performance in, Alzheimer’S. Dis.: A PET Imaging Study [11C]UCB-J. Alzheimer’S. Dement. [Internet], 18, 2527
- Varghese, 2013, A review of neuroimaging biomarkers of Alzheimer’s disease., Neurol. Asia [Internet]
- Wu, 2022, Computed Tomography Density and β-Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease: A 18F-Flutemetamol Positron Emission Tomography/Computed Tomography Study, Front Aging Neurosci. [Internet]
- Dumurgier, 2015, Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: A multicentric study, Alzheimers Res Ther. [Internet], 7, 1
- Hansson, 2023, Blood biomarkers for Alzheimer’s disease in clinical practice and trials, Nat. Aging, 3, 10.1038/s43587-023-00403-3 · DOI · Paper page
- Fabrizio, 2021, Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge?, Diagn. [Internet], 10.3390/diagnostics11081473 · DOI
- Kumar, 2015, A review on Alzheimer’s disease pathophysiology and its management: An update, Vol. 67, 195
- Parums, 2021, Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein, Med Sci. Monit. [Internet]
- Vaz, 2020, Alzheimer’s disease: Recent treatment strategies, Vol. 887
- Tai, 2023, APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies, Alzheimer’S. Dement. [Internet], 10.1002/alz.076888 · doi:10.1002/alz.076888
- Ward, 2021, A phase 1 study of AL002 in healthy volunteers, Alzheimer’S. Dement. [Internet], 10.1002/alz.054669 · DOI
- Reich, 2018, Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease, J. Park. Dis. Alzheimers Dis., 5
- Armijo, 2021, Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic Pathol. Abnorm. a Mouse Model Alzheimer’S. Dis., Vol. 10
- Hashmi, 2023, Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials, Cureus [Internet], 10.7759/cureus.46732 · DOI
- Fariba, 2023, Deep Brain Stimul. Encycl. Mov. Disord., Three-Vol. Set. [Internet].
- Gordon, 2024, Vulnerability in Research: Basic Ethical Concepts and General Approach to Review. Ochsner Journal [Internet], 2020 Mar. 20 [cited
- Shah, 2023, Informed Consent, N. Engl. J. Med [Internet], 376, 863
Cited by
ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025) · Brain Sciences · doi:10.3390/brainsci15020215 · Cited by 35
“Early symptoms include memory problems, sleep issues, and mood disorders, progressing to difficulties in walking and communicating in later stages [4].”
Metadata
- Authors
- Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 101
- Pages
- 102481
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W4402169022
- Cited by
- 371
- References
- 263
- FWCI
- 28.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Institute of Pharmaceutical Education and Research, Raebareli
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.